NASDAQ: BFRGBullfrog Ai Holdings Inc Stock
$2.91+0.05 (+1.75%)
Updated Apr 26, 2024
BFRG Price
$2.91
Fair Value Price
$0.30
Market Cap
$22.85M
52 Week Low
$2.36
52 Week High
$8.35
P/E
-3.27x
P/B
8.81x
P/S
303.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$65.00k
Earnings
-$5.36M
Gross Margin
92%
Operating Margin
-8,118.12%
Profit Margin
-8,239.8%
Debt to Equity
0.07
Operating Cash Flow
-$6M
Beta
1.43
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BFRG Overview
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BFRG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BFRG ($2.91) is overvalued by 878.4% relative to our estimate of its Fair Value price of $0.30 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BFRG ($2.91) is not significantly undervalued (878.4%) relative to our estimate of its Fair Value price of $0.30 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BFRG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BFRG due diligence checks available for Premium users.
Be the first to know about important BFRG news, forecast changes, insider trades & much more!
BFRG News
Valuation
BFRG fair value
Fair Value of BFRG stock based on Discounted Cash Flow (DCF)
Price
$2.91
Fair Value
$0.30
Overvalued by
878.40%
BFRG ($2.91) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BFRG ($2.91) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BFRG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BFRG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.27x
Industry
72.49x
Market
41.14x
BFRG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.81x
Industry
3.38x
BFRG is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BFRG's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.3M
Profit Margin
0%
BFRG's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BFRG's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.8M
Liabilities
$184.4k
Debt to equity
0.07
BFRG's short-term assets ($2.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BFRG's short-term assets ($2.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BFRG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.0M
Investing
$0.0
Financing
-$213.3k
BFRG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BFRG vs Health Information Service Stocks
Bullfrog Ai Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.